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Prognostic serological markers
of Henoch-Scho¨nlein nephritis
Sir,
We read with interest the article on
Henoch-Scho¨nlein purpura with nephritis in adults
by Shrestha et al.1 They point out that there have
been no serological markers of prognosis in
Henoch-Scho¨nlein nephritis (HSN) in both children
and adults. However, a previous report of ours
suggested that the serum IgA/C3 ratio could be a
useful marker of disease activity in children with
severe HSN.2 In this study, the levels of serum IgA or
C3 at presentation were variable, but serial assess-
ment of the serum IgA/C3 ratio (iIgA/C3) showed
a significant correlation with changes in severity
of renal pathology and clinical outcome. High
circulating levels of IgA did not always correlate
with an increase of polymeric IgA1 and mesangial
deposition, and levels of serum C3 are not generally
decreased in HSN. However, the direction of
the changes of IgA and C3 was important, and
correlated with clinical outcome. Therefore, IgA and
C3 may be an important factor in understanding
the pathogenesis of HSN, and the measurement of
serum IgA/C3 ratio may be a useful marker of renal
progression in HSN patients. However, a large
prospective study may be needed to elucidate
whether serum IgA/C3 ratio predicts long-term
prognosis in children and adults with HSN.
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Jellyfish responsible for
Irukandji syndrome
Sir,
I enjoyed the recent letter from Little, Pereira, Carette
and Seymour.1 In a field where so little is known,
all contributions help expand our knowledge
base. However, of the five species presented,
four have been previously linked to Irukandji
syndrome,2–5 and the fifth may be an erroneous
attribution.
Alatina mordens was previously linked with
Irukandji syndrome in its original description,2
which included variation in the number of eyes.
Multiple species may someday be distinguished on
the basis of their eye number as the authors have
suggested, but this has not been demonstrated
taxonomically.
Malo maxima was also previously linked with
Irukandji syndrome in its original description,3
based on numerous eye-witness accounts of sting
events identifying this as the culprit species. The
genus name was derived from a person who survived
a severe sting, believed to be from this species.
’Carybdea alata’ from Hawaii was previously
linked with Irukandji syndrome by Yoshimoto and
Yanagihara,4 although they lacked empirical evi-
dence for positive confirmation. The Hawaiian
species is now formally known as Alatina moseri,
being originally named Carybdea moseri5 and then
transferred to the genus Alatina.2
’Fire jellies’, also commonly called ‘Morbakka’,
were previously linked with mild Irukandji
syndrome by Fenner et al.6 and Williamson et al.7
The more severe case presented by Little et al.1 is
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